Revolution Medicines Appoints Vincent Miller, M.D. To Board Of Directors

REDWOOD CITY, Calif.--(BUSINESS WIRE)--REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced the appointment of Vincent Miller, M.D., to its board of directors. Dr. Miller is a leader in precision oncology enabled by genomic testing and expert in lung cancer, and he will continue to serve as chief medical officer of Foundation Medicine. On the REVOLUTION Medicines board, he replaces Michael Bonney, who has been a director and advisor to the company since its early days and recently joined Kaleido Biosciences as CEO and chairman.

“We are eager to draw on Dr. Miller’s deep expertise in cancer genomics and biomarker-based patient selection as we advance our lead program directed against SHP2, a frontier cancer target presenting significant opportunity,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer. “We recently reported that a proprietary inhibitor of SHP2 suppresses the cancer-promoting effects of selected genetic abnormalities in the RAS/MAP kinase cell growth pathway. Vince is an outstanding addition to REVOLUTION Medicines as we develop our lead compound as targeted therapy for patients with cancers driven by these abnormalities, including non-small cell lung cancer (NSCLC).”

Prior to joining Foundation Medicine, Dr. Miller dedicated over 20 years to cancer patient care and research at Memorial Sloan-Kettering Cancer Center. He is a recognized expert in lung cancer whose research was critical to gaining an understanding of the molecular predictors of sensitivity and resistance to erlotinib and gefitinib in NSCLC. He was also a leader in the development of therapeutic strategies to overcome acquired resistance to these first-generation agents. Dr. Miller received his B.A. from the University of Pennsylvania and M.D. from New Jersey Medical School. He completed his residency at the Thomas Jefferson University Hospital and his fellowship at Memorial Sloan Kettering Cancer Center.

“I am thrilled to join REVOLUTION Medicines at such an exciting time in its pipeline development,” said Dr. Miller. “Recent findings by the company provide a precision medicine framework for approaching genomically-defined cancer targets previously considered undruggable. I look forward to partnering with the team and our collaborators as the company continues its momentum toward the clinic as well as progression of other compelling programs in the pipeline.”

About REVOLUTION Medicines

The mission of REVOLUTION Medicines is to discover and develop new drugs directed toward frontier targets for cancer patients and has a robust pipeline led by its SHP2 program. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investors Third Rock Ventures and The Column Group. For more information, please visit www.revolutionmedicines.com.